<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1816-8949</journal-id>
<journal-title><![CDATA[Anales de la Facultad de Ciencias Médicas (Asunción)]]></journal-title>
<abbrev-journal-title><![CDATA[An. Fac. Cienc. Méd. (Asunción)]]></abbrev-journal-title>
<issn>1816-8949</issn>
<publisher>
<publisher-name><![CDATA[EFACIM. Editorial de la Facultad de Ciencias Médicas - Universidad Nacional de Asunción]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1816-89492020000200053</article-id>
<article-id pub-id-type="doi">10.18004/anales/2020.053.02.53</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Riesgo cardiovascular y uso adecuado de aspirina en prevención primaria de eventos cardiovasculares en el ambulatorio de Clínica Médica del Hospital de Clínicas]]></article-title>
<article-title xml:lang="en"><![CDATA[Cardiovascular risk and adequate use of aspirin in primary prevention of cardiovascular events in the outpatient clinic of Clínica Médica of Hospital de Clínicas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuba]]></surname>
<given-names><![CDATA[María Alejandra Monserrat]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Ciencias Médicas Hospital de Clínicas]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<volume>53</volume>
<numero>2</numero>
<fpage>53</fpage>
<lpage>58</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1816-89492020000200053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1816-89492020000200053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1816-89492020000200053&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  El uso adecuado de la aspirina para la prevención primaria de eventos de enfermedades cardiovasculares requiere de la evaluación de los beneficios y riesgos para el paciente.  Objetivos:  Determinar el riesgo cardiovascular global y el uso adecuado de aspirina como prevención primaria de enfermedades cardiovasculares en pacientes ambulatorios de Clínica Médica del Hospital de Clínicas.  Materiales y métodos:  Estudio observacional, descriptivo, transversal, prospectivo en pacientes ambulatorios de Clínica Médica del Hospital de Clínicas entre setiembre de 2017 y setiembre de 2018. Se incluyó a pacientes de ambos sexos, entre 40 y 79 años de edad, que presentan uno o más de los siguientes factores de riesgo cardiovascular: HTA, dislipidemias, DM2, tabaquismo. Se midieron las variables sociodemográficas, presión arterial sistólica y diastólica, colesterol total, c-HDL, c-LDL, historia de HTA, DM2, tabaquismo, uso de estatinas y ácido acetilsalicílico. Para medir las variables se elaboró un cuestionario. Se calculó el puntaje de riesgo cardiovascular global según ACC/AHA, utilizando la calculadora ASCVD Risk.  Resultados:  Se analizaron 100 cuestionarios, edad promedio de 61±5,3 años, 67% mujeres y el 100% son de raza blanca. El 88% fueron hipertensos, 73% dislipidemicos, 43% diabéticos y 24% tabaquista. El 50% presentaron riesgo cardiovascular global alto, el promedio de riesgo cardiovascular es de 15±3,6 %. El 60% con adecuada indicación de aspirina para la prevención primaria de eventos cardiovasculares.  Conclusión:  La mitad de los pacientes presentaron riesgo cardiovascular alto y en el 60% el uso de aspirina fue adecuado para la prevención primaria de eventos cardiovasculares.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The adequate use of aspirin for the primary prevention of cardiovascular disease events requires the evaluation of the benefits and risks for the patient.  Objectives:  To determine the global cardiovascular risk and the adequate use of aspirin as primary prevention of cardiovascular diseases in outpatients of the Clínica Médica del Hospital de Clínicas.  Materials and methods:  Observational, descriptive, cross-sectional, prospective study in outpatients of the Clínica Médica del Hospital de Clínicas between September 2017 and September 2018. Patients of both sexes, between 40 and 79 years of age, who had one or more of the following cardiovascular risk factors: HT, dyslipidemia, T2DM, smoking. Sociodemographic variables, systolic and diastolic blood pressure, total cholesterol, HDL-c, LDL-c, history of HT, DM2, smoking, use of statins and acetylsalicylic acid were measured. To measure the variables, a questionnaire was prepared. The global cardiovascular risk score was calculated according to ACC / AHA, using the ASCVD Risk calculator.  Results:  100 questionnaires were analyzed, average age of 61 ± 5.3 years, 67% women and 100% are white. 88% were hypertensive, 73% dyslipidemic, 43% diabetic and 24% tobacco addicted. 50% presented high global cardiovascular risk, the average cardiovascular risk is 15 ± 3.6%. 60% with adequate indication of aspirin for the primary prevention of cardiovascular events.  Conclusion:  Half of the patients presented high cardiovascular risk and in 60% the use of aspirin was adequate for the primary prevention of cardiovascular events.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Prevención primaria]]></kwd>
<kwd lng="es"><![CDATA[Aspirina]]></kwd>
<kwd lng="es"><![CDATA[Atención ambulatoria]]></kwd>
<kwd lng="es"><![CDATA[Hipertensión]]></kwd>
<kwd lng="es"><![CDATA[Diabetes]]></kwd>
<kwd lng="es"><![CDATA[Dislipidemias.]]></kwd>
<kwd lng="en"><![CDATA[Primary prevention]]></kwd>
<kwd lng="en"><![CDATA[Aspirin]]></kwd>
<kwd lng="en"><![CDATA[Ambulatory care]]></kwd>
<kwd lng="en"><![CDATA[Hypertension]]></kwd>
<kwd lng="en"><![CDATA[Diabetes]]></kwd>
<kwd lng="en"><![CDATA[Dyslipidemias.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<collab>GBD 2017 Disease and Injury Incidence and Prevalence Collaborators</collab>
<article-title xml:lang=""><![CDATA[Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10159</numero>
<issue>10159</issue>
<page-range>1789-858</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meschia]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Bushnell]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boden-Albala]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Bravata]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Chaturvedi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2014</year>
<volume>45</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3754-832</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riganti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[JVA]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Yanzi]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Kopitowski]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevención primaria cardiovascular y toma de decisiones compartida]]></article-title>
<source><![CDATA[Rev Clin Med Fam]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleites]]></surname>
<given-names><![CDATA[EJQ]]></given-names>
</name>
<name>
<surname><![CDATA[Quintero]]></surname>
<given-names><![CDATA[SFM]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La promoción de la salud y su vínculo con la prevención primaria]]></article-title>
<source><![CDATA[Medicentro]]></source>
<year>2017</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>101-11</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lawes]]></surname>
<given-names><![CDATA[CMM]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Milne]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rodgers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with drugs to lower blood pressure and blood cholesterol based on an individual&#8217;s absolute cardiovascular risk]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2005</year>
<volume>365</volume>
<numero>9457</numero>
<issue>9457</issue>
<page-range>434-41</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mainous]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Tanner]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shorr]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Limacher]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2014</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaziano]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Brotons]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Coppolecchia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cricelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Darius]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gorelick]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10152</numero>
<issue>10152</issue>
<page-range>1036-46</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennekens]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Tonkin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jukema]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Byington]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2004</year>
<volume>164</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McNeil]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mark]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Maderas]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Aspirin on All-Cause Mortality in the Healthy Elderly]]></article-title>
<source><![CDATA[PubMed]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goff]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd-Jones]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Coady]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Agostino]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbons]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2014</year>
<volume>129</volume>
<numero>25 Suppl 2</numero>
<issue>25 Suppl 2</issue>
<page-range>S49-73</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Bairey Merz]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Eckel]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>63</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>2889-934</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridker]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins: new American guidelines for prevention of cardiovascular disease]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2013</year>
<volume>382</volume>
<numero>9907</numero>
<issue>9907</issue>
<page-range>1762-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muntner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Colantonio]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Cushman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goff]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1406-15</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vásquez-Carrillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo-Rivas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar-Nassar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Silva de la Fuente]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Quirós-Meza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Riesgo cardiovascular global en una población adulta mayor del área rural, Cantón de Garabito, Puntarenas]]></article-title>
<source><![CDATA[Acta Médica Costarric]]></source>
<year>2015</year>
<volume>57</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>117-23</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acevedo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valentino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bustamante]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Adasme]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Orellana]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Superioridad del nuevo puntaje de riesgo ACC/AHA 2013 por sobre el puntaje de Framingham, en la predicción de riesgo de mortalidad cardiovascular en Santiago]]></article-title>
<source><![CDATA[Rev Médica Chile]]></source>
<year>2017</year>
<volume>145</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>292-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brítez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maciel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Klinkhof]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mereles]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de factores de riesgo cardiovascular en una población adulta ambulatoria urbana: estudio AsuRiesgo, Paraguay]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2015</year>
<volume>38</volume>
<page-range>136-43</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Briones]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Cartes-Velásquez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de factores de riesgocardiovascular en comunidades pehuenches, Chile]]></article-title>
<source><![CDATA[Rev Médica Electrónica]]></source>
<year>2014</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>34-48</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez S]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva O]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Celis-Morales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de factores de riesgo cardiovascular en trabajadores de la Universidad Austral de Chile]]></article-title>
<source><![CDATA[Rev Chil Nutr]]></source>
<year>2016</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orozco-González]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés-Sanabria]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Viera-Franco]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Márquez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cueto-Manzano]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de factores de riesgo cardiovascular en trabajadores de la salud]]></article-title>
<source><![CDATA[Rev Médica Inst Mex Seguro Soc]]></source>
<year>2016</year>
<volume>54</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>594-601</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira-Rodríguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Peñaranda-Florez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Saenz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Caceres-Arevalo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cañizarez-Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de factores de riesgo cardiovascular en América Latina: una revisión de la evidencia publicada de 2010 a 2015]]></article-title>
<source><![CDATA[Rev. Mex. Cardiol]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guirguis-Blake]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Senger]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Connor]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Whitlock]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2016</year>
<volume>164</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>804-13</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Creager]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Franklin]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2011</year>
<month>;</month>
<volume>58</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2432-46</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mafham]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wallendszus]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Buck]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1529-39</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<collab>Association American Diabetes</collab>
<article-title xml:lang=""><![CDATA[Updates to the Standards of Medical Care in Diabetes-2018]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2018</year>
<volume>41</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2045-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
